751 related articles for article (PubMed ID: 30935424)
1. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib.
Oh CR; Kong SY; Im HS; Kim HJ; Kim MK; Yoon KA; Cho EH; Jang JH; Lee J; Kang J; Park SR; Ryoo BY
BMC Cancer; 2019 Apr; 19(1):292. PubMed ID: 30935424
[TBL] [Abstract][Full Text] [Related]
2. Multiple-level copy number variations in cell-free DNA for prognostic prediction of HCC with radical treatments.
Wang Y; Zhou K; Wang X; Liu Y; Guo D; Bian Z; Su L; Liu K; Gu X; Guo X; Wang L; Zhang H; Tao K; Xing J
Cancer Sci; 2021 Nov; 112(11):4772-4784. PubMed ID: 34490703
[TBL] [Abstract][Full Text] [Related]
3. Early predictive value of circulating biomarkers for sorafenib in advanced hepatocellular carcinoma.
Song S; Bai M; Li X; Gong S; Yang W; Lei C; Tian H; Si M; Hao X; Guo T
Expert Rev Mol Diagn; 2022 Mar; 22(3):361-378. PubMed ID: 35234564
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib.
Chen D; Zhao P; Li SQ; Xiao WK; Yin XY; Peng BG; Liang LJ
Eur J Surg Oncol; 2013 Sep; 39(9):974-80. PubMed ID: 23845703
[TBL] [Abstract][Full Text] [Related]
5. Early decrease in serum amphiregulin or vascular endothelial growth factor levels predicts sorafenib efficacy in hepatocellular carcinoma.
Godin C; Bodeau S; Saidak Z; Louandre C; François C; Barbare JC; Coriat R; Galmiche A; Sauzay C
Oncol Rep; 2019 Mar; 41(3):2041-2050. PubMed ID: 30569112
[TBL] [Abstract][Full Text] [Related]
6. Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial.
Zhu AX; Kang YK; Rosmorduc O; Evans TR; Santoro A; Ross P; Gane E; Vogel A; Jeffers M; Meinhardt G; Peña CE
Clin Cancer Res; 2016 Oct; 22(19):4870-4879. PubMed ID: 27220960
[TBL] [Abstract][Full Text] [Related]
7. Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma.
Personeni N; Rimassa L; Pressiani T; Destro A; Ligorio C; Tronconi MC; Bozzarelli S; Carnaghi C; Di Tommaso L; Giordano L; Roncalli M; Santoro A
J Cancer Res Clin Oncol; 2013 Jul; 139(7):1179-87. PubMed ID: 23568548
[TBL] [Abstract][Full Text] [Related]
8. Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib.
Cho HJ; Kim SS; Nam JS; Oh MJ; Kang DR; Kim JK; Lee JH; Kim B; Yang MJ; Hwang JC; Lim SG; Shin SJ; Lee KM; Yoo BM; Lee KJ; Cho SW; Cheong JY
Cytokine; 2017 Jul; 95():118-125. PubMed ID: 28260649
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma.
Teufel M; Seidel H; Köchert K; Meinhardt G; Finn RS; Llovet JM; Bruix J
Gastroenterology; 2019 May; 156(6):1731-1741. PubMed ID: 30738047
[TBL] [Abstract][Full Text] [Related]
10. Plasma Cell-Free DNA as a Predictive Marker after Radiotherapy for Hepatocellular Carcinoma.
Park S; Lee EJ; Rim CH; Seong J
Yonsei Med J; 2018 Jun; 59(4):470-479. PubMed ID: 29749129
[TBL] [Abstract][Full Text] [Related]
11. SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma.
Lee YS; Kim BH; Kim BC; Shin A; Kim JS; Hong SH; Hwang JA; Lee JA; Nam S; Lee SH; Bhak J; Park JW
Oncotarget; 2015 Jun; 6(18):16449-60. PubMed ID: 25965825
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy.
Kim EJ; Im HS; Lee J; Cho EH; Kim YH; Kim HR; Kim JH; Park SR
Curr Probl Cancer; 2021 Jun; 45(3):100685. PubMed ID: 33342577
[TBL] [Abstract][Full Text] [Related]
13. Plasma Circulating Cell-free DNA in Advanced Hepatocellular Carcinoma Patients Treated With Radiation Therapy.
Kim DY; Cho EH; Kim JS; Chie EK; Kang HC
In Vivo; 2023; 37(5):2306-2313. PubMed ID: 37652507
[TBL] [Abstract][Full Text] [Related]
14. Percentage genome change and chromosome 7q amplification predict sorafenib response in advanced hepatocellular carcinoma.
Yu MC; Wu TH; Lee CW; Lee YS; Lian JH; Tsai CL; Hsieh SY; Tsai CN
Biomed J; 2021 Dec; 44(6 Suppl 1):S73-S83. PubMed ID: 35747997
[TBL] [Abstract][Full Text] [Related]
15. Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
Marisi G; Cucchetti A; Ulivi P; Canale M; Cabibbo G; Solaini L; Foschi FG; De Matteis S; Ercolani G; Valgiusti M; Frassineti GL; Scartozzi M; Casadei Gardini A
World J Gastroenterol; 2018 Sep; 24(36):4152-4163. PubMed ID: 30271080
[TBL] [Abstract][Full Text] [Related]
16. Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib.
Hong YM; Yoon KT; Hwang TH; Heo J; Woo HY; Cho M
Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1250-1255. PubMed ID: 30925530
[TBL] [Abstract][Full Text] [Related]
17. A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma.
Goyal L; Zheng H; Abrams TA; Miksad R; Bullock AJ; Allen JN; Yurgelun MB; Clark JW; Kambadakone A; Muzikansky A; Knowles M; Galway A; Afflitto AJ; Dinicola CF; Regan E; Hato T; Mamessier E; Shigeta K; Jain RK; Duda DG; Zhu AX
Clin Cancer Res; 2019 Jan; 25(1):80-89. PubMed ID: 30190369
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study.
Faloppi L; Puzzoni M; Casadei Gardini A; Silvestris N; Masi G; Marisi G; Vivaldi C; Gadaleta CD; Ziranu P; Bianconi M; Loretelli C; Demurtas L; Lai E; Giampieri R; Galizia E; Ulivi P; Battelli N; Falcone A; Cascinu S; Scartozzi M
Target Oncol; 2020 Feb; 15(1):115-126. PubMed ID: 32020517
[TBL] [Abstract][Full Text] [Related]
19. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.
Horwitz E; Stein I; Andreozzi M; Nemeth J; Shoham A; Pappo O; Schweitzer N; Tornillo L; Kanarek N; Quagliata L; Zreik F; Porat RM; Finkelstein R; Reuter H; Koschny R; Ganten T; Mogler C; Shibolet O; Hess J; Breuhahn K; Grunewald M; Schirmacher P; Vogel A; Terracciano L; Angel P; Ben-Neriah Y; Pikarsky E
Cancer Discov; 2014 Jun; 4(6):730-43. PubMed ID: 24687604
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]